Suppr超能文献

对患者常规给药期间维拉帕米蓄积原因的调查。

An investigation of the cause of accumulation of verapamil during regular dosing in patients.

作者信息

Schwartz J B, Abernethy D R, Taylor A A, Mitchell J R

出版信息

Br J Clin Pharmacol. 1985 Apr;19(4):512-6. doi: 10.1111/j.1365-2125.1985.tb02678.x.

Abstract

The accumulation of verapamil during regular dosing conditions was studied. Plasma concentrations of verapamil (V) and norverapamil (NV) were measured as were urinary concentrations of verapamil, norverapamil, and four other N- and O-dealkylated metabolites in nine patients after an initial single dose and after chronic oral verapamil administration to steady-state plasma concentrations. Indocyanine green (ICG) clearance was determined immediately prior to the initial verapamil dose and prior to the verapamil washout from regular dosing. An approximately two-fold accumulation of V had occurred during regular dosing. The area under the plasma concentration-time curve (AUC1) after the first dose was 417.4 +/- 276.7 ng ml-1 h (mean +/- s.d.) and increased to 786.5 +/- 54 ng ml-1 h (P less than 0.01) during one dosage interval at steady-state (AUCss). NV also tended to accumulate from an AUC1 of 552.6 +/- 411 to an AUCss 668.7 +/- 332 ng ml-1 h (P less than 0.09). The ratio of AUC-V to AUC-NV was unchanged. The verapamil elimination half-life (t 1/2) increased from 8.4 +/- 4.2 to 12.0 +/- 3.6 h (P less than 0.01) whereas the norverapamil t 1/2 was unchanged. ICG clearance was unchanged. Urinary excretion of NV increased slightly but the ratio of urinary V/NV concentrations was not significantly altered nor was the ratio of four other metabolites to verapamil or the ratio of the combined o-demethylated to the N-dealkylated metabolites.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

研究了常规给药条件下维拉帕米的蓄积情况。在9名患者单次初始给药后以及慢性口服维拉帕米至稳态血药浓度后,测定了维拉帕米(V)和去甲维拉帕米(NV)的血浆浓度,以及维拉帕米、去甲维拉帕米和其他4种N - 去烷基化和O - 去烷基化代谢物的尿浓度。在初始维拉帕米给药前以及常规给药的维拉帕米清除前,测定了吲哚菁绿(ICG)清除率。常规给药期间V出现了约2倍的蓄积。首剂后的血浆浓度 - 时间曲线下面积(AUC1)为417.4±276.7 ng·ml⁻¹·h(均值±标准差),在稳态时的一个给药间隔期间(AUCss)增至786.5±54 ng·ml⁻¹·h(P<0.01)。NV也有蓄积倾向,AUC1为552.6±411,AUCss为668.7±332 ng·ml⁻¹·h(P<0.09)。AUC - V与AUC - NV的比值未变。维拉帕米消除半衰期(t₁/₂)从8.4±4.2小时增至12.0±3.6小时(P<0.01),而去甲维拉帕米的t₁/₂未变。ICG清除率未变。NV的尿排泄略有增加,但尿中V/NV浓度比值未显著改变,其他4种代谢物与维拉帕米的比值以及O - 去甲基化代谢物与N - 去烷基化代谢物的合并比值也未改变。(摘要截短于250词)

相似文献

1
An investigation of the cause of accumulation of verapamil during regular dosing in patients.
Br J Clin Pharmacol. 1985 Apr;19(4):512-6. doi: 10.1111/j.1365-2125.1985.tb02678.x.
2
Pharmacokinetics of verapamil in patients with hypertension.
Eur J Clin Pharmacol. 1986;31(2):155-63. doi: 10.1007/BF00606652.
3
Prolongation of verapamil elimination kinetics during chronic oral administration.
Am Heart J. 1982 Aug;104(2 Pt 1):198-203. doi: 10.1016/0002-8703(82)90192-2.
4
Reduced verapamil clearance during long-term oral administration.
Clin Pharmacol Ther. 1981 Nov;30(5):701-6. doi: 10.1038/clpt.1981.223.
6
Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment.
Ther Drug Monit. 1995 Feb;17(1):60-7. doi: 10.1097/00007691-199502000-00010.
7
In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
Clin Pharmacol Ther. 1999 Jul;66(1):40-50. doi: 10.1016/S0009-9236(99)70052-4.
8
Pharmacokinetics of verapamil and norverapamil during long-term oral therapy.
Res Commun Chem Pathol Pharmacol. 1983 Apr;40(1):15-27.

引用本文的文献

2
The effect of oral verapamil therapy on antipyrine clearance.
Br J Clin Pharmacol. 1986 Nov;22(5):606-9. doi: 10.1111/j.1365-2125.1986.tb02942.x.
3
Verapamil pharmacokinetics.
Br J Clin Pharmacol. 1986 May;21(5):554-5. doi: 10.1111/j.1365-2125.1986.tb02846.x.
4
Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.
Clin Pharmacokinet. 1986 Nov-Dec;11(6):425-49. doi: 10.2165/00003088-198611060-00002.
5
Pharmacokinetics and pharmacodynamics of two formulations of verapamil.
Br J Clin Pharmacol. 1987 Nov;24(5):661-4. doi: 10.1111/j.1365-2125.1987.tb03226.x.
6
Pharmacokinetics of calcium antagonists under development.
Clin Pharmacokinet. 1988 Jul;15(1):1-14. doi: 10.2165/00003088-198815010-00001.
8
Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy.
Br J Clin Pharmacol. 1989 Sep;28(3):357-61. doi: 10.1111/j.1365-2125.1989.tb05438.x.
10
Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man.
Eur J Clin Pharmacol. 1989;37(3):313-6. doi: 10.1007/BF00679792.

本文引用的文献

2
Reduced verapamil clearance during long-term oral administration.
Clin Pharmacol Ther. 1981 Nov;30(5):701-6. doi: 10.1038/clpt.1981.223.
3
Verapamil kinetics in normal subjects and patients with coronary artery spasm.
Clin Pharmacol Ther. 1981 Nov;30(5):644-52. doi: 10.1038/clpt.1981.216.
4
Verapamil disposition kinetics in chronic atrial fibrillation.
Clin Pharmacol Ther. 1981 Jul;30(1):44-51. doi: 10.1038/clpt.1981.125.
5
Simultaneous determination of verapamil and its seven metabolites by high-performance liquid chromatography.
J Chromatogr. 1981 Mar 13;222(3):507-11. doi: 10.1016/s0378-4347(00)84156-0.
7
Prolongation of verapamil elimination kinetics during chronic oral administration.
Am Heart J. 1982 Aug;104(2 Pt 1):198-203. doi: 10.1016/0002-8703(82)90192-2.
8
Prediction of steady-state verapamil plasma concentrations in children and adults.
Clin Pharmacol Ther. 1982 Aug;32(2):172-81. doi: 10.1038/clpt.1982.144.
9
Application of stable labelled drugs in clinical pharmacokinetic investigations.
Clin Pharmacokinet. 1982 Nov-Dec;7(6):490-507. doi: 10.2165/00003088-198207060-00002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验